Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation

Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06572930

Acronym

FSH

Enrollment

150

Registered

2024-08-27

Start date

2024-12-16

Completion date

2026-12-01

Last updated

2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Stimulation

Keywords

ovarian response, stimulation protocols, stimulation monitoring, follicular stimulating hormone

Brief summary

This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.

Detailed description

Ovarian stimulation typically uses transvaginal ultrasound to monitor follicle growth and endometrial condition, with some clinics also tracking serum estradiol and progesterone levels, but often neglecting serum Follicle Stimulation Hormone (FSH). FSH is essential for follicle development, yet its levels can vary widely among women receiving the same dose due to factors like body weight, renal function, and ovarian reserve. This study aims to identify a minimum effective FSH threshold that ensures optimal follicular growth while avoiding excess administration.

Interventions

DRUGGonal-f (gonadotropin)

Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 39 Years

Healthy volunteers

Yes

Inclusion criteria

* regular 21 - 35 days cycles * BMI between 19 - 30 kg/m2 * serum AMH level between 1.5 to 3 ng/ml * a total antral follicle count between 10 to 24 * endogenous early follicular phase serum FSH level \<10 IU/L * normal glomerular filtration rate

Exclusion criteria

* hypogonadotropic hypogonadism * history of ovarian surgery * permanent ovarian cysts of any form * older than 39 years * abnormal thyroid stimulating hormone (TSH) * renal disease * elevated prolactin levels * intake of oral contraceptives 3 months before stimulation start and estradiol pretreatment will be excluded

Design outcomes

Primary

Measure	Time frame	Description
Quantitative Measurement of Serum Follicle-Stimulating Hormone (FSH) Levels During Ovarian Stimulation Using Serum Assays.	1 year	serum FSH levels during ovarian stimulation

Countries

United Arab Emirates

Contacts

CONTACTJonalyn Edades

jonalyn.edades@artfertilityclinics.com+971526408688

CONTACTBaris Ata, MD

baris.ata@artfertilityclinics.com+971504374824

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026